Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study

Cardiovascular Diabetology

Original Investigation

Giuseppe Montalto¹  Angelo Maria Patti¹  Vittoria Di Bartolo¹  Manfredi Rizzo²  Ali A Rizvi³  Manisha Chandalia⁴  Nicola Abate⁴ 

[1] Biomedical Department of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy;Biomedical Department of Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy;Euro-Mediterranean Institute of Science and Technology, Palermo, Italy;Division of Endocrinology, Diabetes and Metabolism, University of South Carolina School of Medicine, Columbia, South Carolina, USA;Division of Endocrinology, Diabetes and Metabolism, University of South Carolina School of Medicine, Columbia, South Carolina, USA;Division of Endocrinology, The University of Texas Medical Branch, 8.138 Medical Research Building, 301 University Boulevard, 77555-1060, Galveston, TX, USA;

关键词: Liraglutide;    Carotid intima-media thickness;    Cardiovascular risk;    Type2 diabetes;   

DOI  :  10.1186/1475-2840-13-49

 received in 2013-11-04, accepted in 2014-01-29,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundLiraglutide, a long-acting glucagon-like peptide-1 (GLP-1) analog, has several non- glycemic properties, but its effect on carotid intima-media thickness (IMT), a recognized marker of subclinical atherosclerosis, is still unknown.MethodsA prospective study of 8 months duration in 64 patients with type-2 diabetes and no prior history of coronary artery disease evaluated whether adding liraglutide to metformin affects carotid IMT, measured by color doppler ultrasound.ResultsAfter 8 months, fasting glucose decreased by 2.1 mmol/l and HbA1c by 1.9% (p < 0.01 for all). Liraglutide reduced total-cholesterol and triglycerides by 10%, and LDL-cholesterol by 19%, whereas HDL-cholesterol increased by 18% (p < 0.01 for all lipid changes). Carotid IMT decreased from 1.19 ± 0.47 to 0.94 ± 0.21 mm (p < 0.01). Yet, changes in carotid IMT did not correlate with changes in any other variable studied.ConclusionsLiraglutide decreases carotid IMT after 8 months treatment independently of its effect on plasma glucose and lipids concentrations.Trial registrationClinicalTrials.gov: NCT01715428.

【 授权许可】

Unknown   
© Rizzo et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.